MRNA in Exosomas As a Liquid Biopsy in Non-Hodgkin Lymphoma: a Multicentric Study by the Spanish Lymphoma Oncology Group

Overview

Journal Oncotarget

Specialty Oncology

Date 2017 Sep 9

PMID 28881619

Citations 25

Authors

Mariano Provencio

Marta Rodriguez

Blanca Cantos

Pilar Sabin

Cristina Quero

Francisco R Garcia-Arroyo

Antonio Rueda

Constanza Maximiano

Delvys Rodriguez-Abreu

Antonio Sanchez

Javier Silva

Vanesa Garcia

Affiliations

Soon will be listed here.

Abstract

Purpose: To determine the feasibility of mRNAs ( and ) in exosomes of plasma as a liquid biopsy method for monitoring and prognostic evolution in B-cell lymphomas.

Patients And Methods: Exosomes were isolated from 98 patients with B-cell Lymphoma and 68 healthy controls. mRNAs were analyzed by quantitative PCR. An additional 31 post-treatment samples were also studied.

Results: In the general and follicular lymphoma series, the presence of mRNA was associated with poor response to rituximab-based treatment. Patients with first relapse or disease progression showed a lower percentage of and mRNA. The presence of mRNA was associated with a high death rate. The absence of mRNA in the general series, and presence of mRNA in follicular lymphomas, were associated with short progression-free survival. and mRNA were independent prognostic variables of overall survival. mRNA may provide prognostic information with respect to overall survival. mRNA and increase of mRNA in post-treatment samples could serve as molecular monitoring markers.

Conclusions: This is the first large study to evaluate the prognostic and predictive values of pretreatment tumor-associated mRNA in exosomes. BCL-6 and C-MYC mRNA positivity in pretreatment samples were predictors of worse PFS compared to patients with mRNA negativity. C-MYC mRNA positivity was also a statistically significant predictor of inability to obtain complete response with first-line therapy.

Citing Articles

The multifaceted roles of extracellular vesicles for therapeutic intervention with non-Hodgkin lymphoma.

Lee A, Godwin A, Abdelhakim H Extracell Vesicles Circ Nucl Acids. 2024; 5(2):329-343.

PMID: 39639879 PMC: 11618822. DOI: 10.20517/evcna.2024.07.

Molecular Biomarkers in Prediction of High-Grade Transformation and Outcome in Patients with Follicular Lymphoma: A Comprehensive Systemic Review.

Enemark M, Hemmingsen J, Jensen M, Kridel R, Ludvigsen M Int J Mol Sci. 2024; 25(20).

PMID: 39456961 PMC: 11508793. DOI: 10.3390/ijms252011179.

Liquid biopsy for CNS lymphoma: CSF exosomes and CSF exosomal miR-15a, miR-21, miR-155, miR-210, and miR-19b are promising biomarkers for diagnosis.

Hatiboglu M, Karacam B, Khan I, Akdur K, Elbasan E, Mahfooz S Mol Biol Rep. 2024; 51(1):1035.

PMID: 39361107 DOI: 10.1007/s11033-024-09967-8.

Exploring the cell-free total RNA transcriptome in diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma patients as biomarker source in blood plasma liquid biopsies.

Decruyenaere P, Giuili E, Verniers K, Anckaert J, De Grove K, Van der Linden M Front Oncol. 2023; 13:1221471.

PMID: 37954086 PMC: 10634215. DOI: 10.3389/fonc.2023.1221471.

Extracellular vesicles in hematological malignancies: EV-dence for reshaping the tumoral microenvironment.

Van Morckhoven D, Dubois N, Bron D, Meuleman N, Lagneaux L, Stamatopoulos B Front Immunol. 2023; 14:1265969.

PMID: 37822925 PMC: 10562589. DOI: 10.3389/fimmu.2023.1265969.

References

Rodriguez M, Silva J, Lopez-Alfonso A, Lopez-Muniz M, Pena C, Dominguez G . Different exosome cargo from plasma/bronchoalveolar lavage in non-small-cell lung cancer. Genes Chromosomes Cancer. 2014; 53(9):713-24. DOI: 10.1002/gcc.22181. View

Cai Q, Medeiros L, Xu X, Young K . MYC-driven aggressive B-cell lymphomas: biology, entity, differential diagnosis and clinical management. Oncotarget. 2015; 6(36):38591-616. PMC: 4770723. DOI: 10.18632/oncotarget.5774. View

Cheson B, Horning S, Coiffier B, Shipp M, Fisher R, Connors J . Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999; 17(4):1244. DOI: 10.1200/JCO.1999.17.4.1244. View

Choi W, Weisenburger D, Greiner T, Piris M, Banham A, Delabie J . A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res. 2009; 15(17):5494-502. PMC: 7289055. DOI: 10.1158/1078-0432.CCR-09-0113. View

Xu P, Zhang W, Cai X, Qiu P, Hao M, Lu D . Activating AKT to inhibit JNK by troxerutin antagonizes radiation-induced PTEN activation. Eur J Pharmacol. 2016; 795:66-74. DOI: 10.1016/j.ejphar.2016.11.052. View

Garcia V, Garcia J, Silva J, Martin P, Pena C, Dominguez G . Extracellular tumor-related mRNA in plasma of lymphoma patients and survival implications. PLoS One. 2009; 4(12):e8173. PMC: 2788245. DOI: 10.1371/journal.pone.0008173. View

Suzuki E, Umezawa K, Bonavida B . Rituximab inhibits the constitutively activated PI3K-Akt pathway in B-NHL cell lines: involvement in chemosensitization to drug-induced apoptosis. Oncogene. 2007; 26(42):6184-93. DOI: 10.1038/sj.onc.1210448. View

Jazirehi A, Vega M, Bonavida B . Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy. Cancer Res. 2007; 67(3):1270-81. DOI: 10.1158/0008-5472.CAN-06-2184. View

Rosenthal A, Younes A . High grade B-cell lymphoma with rearrangements of MYC and BCL2 and/or BCL6: Double hit and triple hit lymphomas and double expressing lymphoma. Blood Rev. 2016; 31(2):37-42. PMC: 5572137. DOI: 10.1016/j.blre.2016.09.004. View

10.

Meyer P, Fu K, Greiner T, Smith L, Delabie J, Gascoyne R . Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. J Clin Oncol. 2010; 29(2):200-7. PMC: 3058275. DOI: 10.1200/JCO.2010.30.0368. View

11.

Aung T, Chapuy B, Vogel D, Wenzel D, Oppermann M, Lahmann M . Exosomal evasion of humoral immunotherapy in aggressive B-cell lymphoma modulated by ATP-binding cassette transporter A3. Proc Natl Acad Sci U S A. 2011; 108(37):15336-41. PMC: 3174603. DOI: 10.1073/pnas.1102855108. View

12.

Compagno M, Lim W, Grunn A, Nandula S, Brahmachary M, Shen Q . Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature. 2009; 459(7247):717-21. PMC: 2973325. DOI: 10.1038/nature07968. View

13.

Barrans S, Crouch S, Smith A, Turner K, Owen R, Patmore R . Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol. 2010; 28(20):3360-5. DOI: 10.1200/JCO.2009.26.3947. View

14.

Obermann E, Csato M, Dirnhofer S, Tzankov A . Aberrations of the MYC gene in unselected cases of diffuse large B-cell lymphoma are rare and unpredictable by morphological or immunohistochemical assessment. J Clin Pathol. 2009; 62(8):754-6. DOI: 10.1136/jcp.2009.065227. View

15.

Majchrzak A, Witkowska M, Smolewski P . Inhibition of the PI3K/Akt/mTOR signaling pathway in diffuse large B-cell lymphoma: current knowledge and clinical significance. Molecules. 2014; 19(9):14304-15. PMC: 6271242. DOI: 10.3390/molecules190914304. View

16.

Bonavida B . Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions. Oncogene. 2007; 26(25):3629-36. DOI: 10.1038/sj.onc.1210365. View

17.

Zhang H, Grizzle W . Exosomes and cancer: a newly described pathway of immune suppression. Clin Cancer Res. 2011; 17(5):959-64. PMC: 3155407. DOI: 10.1158/1078-0432.CCR-10-1489. View

18.

Melani C, Roschewski M . Molecular Monitoring of Cell-Free Circulating Tumor DNA in Non-Hodgkin Lymphoma. Oncology (Williston Park). 2016; 30(8):731-8, 744. View

19.

Elstrom R, Andemariam B, Martin P, Ruan J, Shore T, Coleman M . Bortezomib in combination with rituximab, dexamethasone, ifosfamide, cisplatin and etoposide chemoimmunotherapy in patients with relapsed and primary refractory diffuse large B-cell lymphoma. Leuk Lymphoma. 2012; 53(8):1469-73. DOI: 10.3109/10428194.2012.656629. View

20.

Lenz G, Nagel I, Siebert R, Roschke A, Sanger W, Wright G . Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell-like diffuse large B cell lymphoma. J Exp Med. 2007; 204(3):633-43. PMC: 2137913. DOI: 10.1084/jem.20062041. View